ALPI and inflammatory bowel disease: Tuin et al. found that IAP gene expression was significantly lower in patients with inflammatory bowel diseases (IBDs), including Crohn’s disease and ulcerative colitis, and cIAP treatment prevented colonic inflammation in a dextran sulfate sodium-induced rodent model of IBD [5].